Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NSD2 is an actionable driver of prostate cancer metastasis

ABSTRACT: NSD2 is an actionable driver of prostate cancer metastasis

PROVIDER: PRJNA487359 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6794330.fastq.gz	Fastqsanger.gz
	SRR6794340.fastq.gz	Fastqsanger.gz
	SRR6794350.fastq.gz	Fastqsanger.gz
	SRR6794360.fastq.gz	Fastqsanger.gz
	SRR6794321.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 75

Similar Datasets

NSD2 is a conserved driver of metastatic prostate cancer progression.

Project description:NSD2 is a conserved driver of metastatic prostate cancer progression.

| PRJNA436465 | ENA

NSD2 is an actionable driver of prostate cancer metastasis

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-12-07 | GSE118936 | GEO

Targeting NSD2 in mouse prostate cancer cells

Project description:Transcriptome analysis of mouse prostate cancer cell line (NPK) silenced for Nsd2 using shRNA or treated with MCTP--39. NPK prostatre cancer cells are derived Nkx3.1CreERT2/+ ;Ptenflox/flox;KrasLSL-G12D/+ mice, and were used to silence the histone methyltransferase NSD2 or treat them with the NSD2 inhibitor MCTP39 for subsequent gene expression profiling by RNAseq

2019-07-23 | GSE118784 | GEO

Tiam1 methylation by NSD2 promotes Rac1 signaling activation and cancer metastasis

Project description:Metastasis is the key cause of failure of cancer therapy or mortality, but targeting metastatic seeding and colonization remains an unresolved challenge. Here, we report a novel molecular event in cancer metastasis mediated by NSD2/Rac1 signaling and provide a detailed mechanistic investigation of cancer metastasis. We found that NSD2, a histone methyltransferase responsible for di-methylating histone 3 at lysine 36, was overexpressed in metastatic tumors, and overexpressed NSD2 enhanced tumor metastasis both in vitro and in vivo. We further investigated that NSD2 promoted tumor metastasis by activating the Rac1 signaling pathway. Mechanistically, NSD2 methylated Tiam1, a guanine nucleotide exchange factor that facilitates GDP-Rac1 to GTP-Rac1 transition at K724. We demonstrated that Tiam1 K724 methylation plays a crucial role in Tiam1 activation and GDP-Rac1 to GTP-Rac1 transition. Specifically, we identified that Tiam1 K724 methylation could be a predictive factor in cancer prognosis, and we demonstrated that pharmacological blocking of Tiam1 K724 methylation by employing a transmembrane peptide inhibited tumor metastasis both in vitro and in vivo. Thus, NSD2-methylated Tiam1 promoted Rac1 signaling activation and cancer metastasis, which might provide novel insights into tumor metastasis inhibition.

2023-07-23 | GSE237714 | GEO

Tiam1 methylation by NSD2 promotes Rac1 signaling activation and cancer metastasis II

2023-07-29 | GSE237996 | GEO

NSD2 is a conserved driver of metastatic prostate cancer progression.

Project description:Analysis of transcriptome of FACS isolated cancer cells from prostate primary tumors and metastasis from NPK GEM models

2018-12-05 | GSE111291 | GEO

In Vivo Genome-Wide CRISPR Screening Identifies CITED2 as a Driver of Prostate Cancer Bone metastasis

Project description:Most cancer deaths are due to metastatic dissemination to distant organs. Bone is the most frequently affected organ in metastatic prostate cancer and a major cause of prostate cancer deaths. Yet, our partial understanding of the molecular factors that drive bone metastasis has been a limiting factor for developing preventative and therapeutic strategies to improve patient survival and well-being. Although recent studies have uncovered molecular alterations that occur in prostate cancer metastasis, their functional relevance for bone metastasis is not well understood. Using genome-wide CRISPR activation and inhibition screens we have identified multiple drivers and suppressors of prostate cancer metastasis. Through functional validation, including innovative organ-on-a-chip invasion platform for studying bone tropism, our study identifies the transcriptional modulator, CITED2, as a novel driver of prostate cancer bone metastasis and uncovers multiple new potential molecular targets for bone metastatic disease.

2024-02-22 | GSE253815 | GEO

Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis

Project description:To study genetic factors that influence the progression and therapeutic response of advanced prostate cancer, we developed a fast and flexible system that introduces genetic alterations relevant to human disease directly into the prostate glands of mice using tissue electroporation. These electroporation based genetically engineered mouse models (EPO-GEMM) recapitulate features of traditional germline models and, by modeling genetic factors linked to late stage human disease, can produce tumors that are metastatic and castration resistant. Unexpectedly, a subset of particularly metastatic tumors acquired WNT pathway alterations, which are also associated with metastatic prostate cancer in humans. Harnessing features linked to the EPO-GEMM approach, we validate the WNT pathway as a key event in driving metastatic disease, a finding that we confirm in an orthogonal approach using mouse prostate organoids. Moreover, we show that tumors harboring WNT pathway alterations are sensitive to pharmacological WNT pathway inhibition. Thus, by leveraging the power of EPO-GEMMs, our studies reveal a functional role for WNT signaling in driving prostate cancer metastasis and validate the WNT pathway as an actionable therapeutic target in metastatic prostate cancer.

2020-04-28 | GSE139340 | GEO

Epigenetic Activation and alteration of chromatin structure regulated by NSD2 in metastatic castration-resistant prostate cancer (ChIP-seq)

Project description:To elucidate the regulation of NSD2 in metastatic castration-resistant prostate cancer(CRPC), we performed ChIP-seq of H3K36me2, H3K27me3, H3K4me1, H3K4me3,H3K27ac and NSD2 against castration-sensitive prostate cancer cell line LNCaP and metastatic castration-resistant prostate cancer cell lines, PC3 and DU145, respectively. In metastatic CRPC, we found specific regions of activation with epigenetic changes.

2024-09-04 | GSE248629 | GEO

Epigenetic Activation and alteration of chromatin structure regulated by NSD2 in metastatic castration-resistant prostate cancer (RNA-seq)

2024-09-04 | GSE248628 | GEO